Krystal Biotech director Gangolli Julian S received 1,658 derivative securities across two transactions dated Sep. 14, with each priced at $0 per share. The award changes the director’s reported derivative position and gives investors a specific record of the transaction type, date and stated price.

Key Highlights

  • The transactions were classified under code A, which denotes an award or grant.
  • Gangolli Julian S completed the transactions on 14 September 2026.
  • The derivative securities carried a stated price of $0 per share.

Krystal Biotech, Inc. (NASDAQ: KRYS) awarded director Gangolli Julian S a total of 1,658 derivative securities. The transactions were dated 14 September 2026 and carried a stated price of $0 per share, marking a change in the director’s reported derivative position. The award was recorded across two separate transactions. Both entries used transaction code A, the classification for an award or grant. Gangolli Julian S was identified as a director of Krystal Biotech, Inc. The securities were derivative instruments rather than common stock, and the stated per-share price was $0. The transaction date was 14 September 2026.

Award Details and Transaction Classification

The entries were recorded separately but carried the same transaction classification. Code A identifies the activity as an award or grant, rather than an open-market purchase or sale. Gangolli Julian S was the individual associated with the transactions, and Krystal Biotech, Inc. was the company named in the record. The transaction record therefore identifies the quantity, classification, date and price attached to the director’s derivative securities award.